Stem cells for Duchenne?

Adult stem cells taken from humans suffering from Duchenne muscular dystrophy can be genetically modified and used to treat the disease in a mouse model, researchers linkurl:report;http://www.cellstemcell.com/ today in Cell Stem Cell. Duchenne muscular dystrophy is a progressive condition caused by a mutation on the X chromosome that leads to a lack of dystrophin protein in muscle. The mutation is usually caused by a deletion or mutation in the gene, leading to a shift in the reading frame of m

Written byAlla Katsnelson
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Adult stem cells taken from humans suffering from Duchenne muscular dystrophy can be genetically modified and used to treat the disease in a mouse model, researchers linkurl:report;http://www.cellstemcell.com/ today in Cell Stem Cell. Duchenne muscular dystrophy is a progressive condition caused by a mutation on the X chromosome that leads to a lack of dystrophin protein in muscle. The mutation is usually caused by a deletion or mutation in the gene, leading to a shift in the reading frame of mRNA translation. In past studies, injecting Duchenne mice with normal muscle cells has temporarily staved off disease symptoms, but that technique does not work reliably and can cause immune rejection. So researchers have linkurl:proposed;http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=16691118&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum delivering muscle progenitor cells instead. Yvan Torrente of the University of Milan, Italy, and colleagues took human blood- and muscle-derived stem cells from Duchenne patients. They used linkurl:antisense oligonucleotides;http://www.the-scientist.com/article/display/21438/ delivered by linkurl:lentiviral vectors;http://www.the-scientist.com/article/display/19298/ to mask the incorrect mRNA splicing sites, thus returning translation to its normal reading frame. They then intramuscularly injected the corrected cells into the sick mice. Within three weeks, the transplanted cells gave rise to muscle fibers and spurred production of the dystrophin protein. The authors caution, however, that using viral vectors may cause tumor formation, and that details of the technique such as its efficiency remain to be worked out. Both the antisense techniques and muscle cell transplantation have been tried before in Duchenne, note linkurl:Kay Davis;http://www.hertford.ox.ac.uk/main/content/view/155/249/ of Oxford University and linkurl:Miranda Grounds;http://school.anhb.uwa.edu.au/personalpages/grounds/ of the University of Western Australia in an accompanying review article. But the combination of the two makes this a proof of principle study that shows that "steady progress is being made toward the goal of stem cell-mediated restoration of dystrophin expression," they write.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies